Abstract
Alzheimer’s Disease (AD) affects about 24 million people worldwide and costs Americans billions of dollars every year.1 With the prevalence of AD, treatments are needed to combat the disease and reduce its effect. In the past, cholinesterase inhibitors were used to treat the symptoms of the disease. In recent years, however, a new type of drug, monoclonal antibody, has been used for the treatment of AD. The purpose of this paper is to review the old and new Alzheimer’s treatment through the lens of affordability and accessibility, and provide insight into the future of the treatment options. In the end, innovative treatments such as vaccines and targeting different mechanisms of action are the next step in Alzheimer’s treatment. Access to these treatments should be more readily available and affordable to low-income families. To support this, the FDA should modify its accelerated approval program to reward rigorous scientific research.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
